This study highlights the potential of combined trastuzumab and PARP inhibition in HER2+ breast cancer, while demonstrating a need for optimization of [18F]FLT–PET quantification in heterogeneous models of HER2+ breast cancer. Here, ERBB2 is linked to breast cancer.